The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat some patients with mild cognitive impairment in the early stages of Alzheimer's disease, ending a more than ...

Celltrion, a major Korean biopharmaceutical firm, said Monday its new biosimilar for an autoimmune disease treatment has ...